Edwards Lifesciences Corporation (NYSE: EW) is -3.06% lower on its value in year-to-date trading and has touched a low of $51.51 and a high of $92.08 in the current 52-week trading range. The EW stock was last observed hovering at around $88.92 in the last trading session, with the day’s loss setting it -0.48% off its average median price target of $94.00 for the next 12 months. It is also 20.32% off the consensus price target high of $111.00 offered by 25 analysts, but current levels are -30.06% lower than the price target low of $68.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $88.44, the stock is 1.58% and 6.37% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.58 million and changing -0.54% at the moment leaves the stock 15.14% off its SMA200. EW registered 13.00% gain for a year compared to 6-month gain of 28.98%. The firm has a 50-day simple moving average (SMA 50) of $86.04 and a 200-day simple moving average (SMA200) of $79.87.
The stock witnessed a 5.73% loss in the last 1 month and extending the period to 3 months gives it a 10.34%, and is -2.36% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.44% over the week and 2.44% over the month.
Edwards Lifesciences Corporation (EW) has around 13900 employees, a market worth around $54.16B and $4.37B in sales. Current P/E ratio is 70.64 and Fwd P/E is 41.15. Profit margin for the company is 18.20%. Distance from 52-week low is 71.71% and -3.95% from its 52-week high. The company has generated returns on investments over the last 12 months (21.70%).
Edwards Lifesciences Corporation (EW) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Edwards Lifesciences Corporation (EW) is a “Overweight”. 25 analysts offering their recommendations for the stock have an average rating of 2.20, where 10 rate it as a Hold and 1 think it is a “Overweight”. 12 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Edwards Lifesciences Corporation is expected to release its quarterly report on 04/27/2021 and quarterly earnings per share for the current quarter are estimated at $0.53 with sales reaching $1.19B over the same period.The EPS is expected to grow by 43.20% this year, but quarterly earnings will post 0.90% year-over-year. Quarterly sales are estimated to grow 1.30% in year-over-year returns.
Edwards Lifesciences Corporation (EW) Top Institutional Holders
1,520 institutions hold shares in Edwards Lifesciences Corporation (EW), with 4.26M shares held by insiders accounting for 0.68% while institutional investors hold 88.19% of the company’s shares. The shares outstanding are 622.10M, and float is at 618.98M with Short Float at 0.80%. Institutions hold 87.59% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 59.04 million shares valued at $4.71 billion. The investor’s holdings represent 9.47% of the EW Shares outstanding. As of Sep 29, 2020, the second largest holder is Vanguard Group, Inc. (The) with 48.84 million shares valued at $3.9 billion to account for 7.84% of the shares outstanding. The other top investors are State Street Corporation which holds 26.75 million shares representing 4.29% and valued at over $2.14 billion, while Bank Of New York Mellon Corporation holds 3.31% of the shares totaling 20.6 million with a market value of $1.64 billion.
Edwards Lifesciences Corporation (EW) Insider Activity
The most recent transaction is an insider sale by Lemercier Jean-Luc M, the company’s CVP, EMEA, Canada, Latin Amer. SEC filings show that Lemercier Jean-Luc M sold 20,523 shares of the company’s common stock on Jan 04 at a price of $91.24 per share for a total of $1.87 million. Following the sale, the insider now owns 0.14 million shares.
Edwards Lifesciences Corporation disclosed in a document filed with the SEC on Dec 15 that Wood Larry L (CVP, TAVR) sold a total of 10,722 shares of the company’s common stock. The trade occurred on Dec 15 and was made at $84.21 per share for $0.9 million. Following the transaction, the insider now directly holds 0.36 million shares of the EW stock.
Still, SEC filings show that on Dec 14, MUSSALLEM MICHAEL A (Chairman & CEO) disposed off 68,550 shares at an average price of $84.49 for $5.79 million. The insider now directly holds 241,220 shares of Edwards Lifesciences Corporation (EW).
Edwards Lifesciences Corporation (EW): Who are the competitors?
The company’s main competitors (and peers) include Boston Scientific Corporation (BSX) that is trading -20.09% down over the past 12 months. Medtronic plc (MDT) is 1.79% up on the 1-year trading charts. Short interest in the company’s stock has fallen -2.03% from the last report on Nov 12, 2020 to stand at a total of 5.02 million short shares sold with a short interest ratio of 1.96.